What assessment finding should concern the nurse most in a client who is preparing to take a CNS stimulant drug?

Rationale: A. Inability to concentrate: Difficulty concentrating is often a symptom for which CNS stimulants are prescribed, such as in ADHD or narcolepsy. While it is important to assess baseline cognitive function, this finding does not contraindicate stimulant use and is not the most concerning pre-administration assessment. B. Symptomatic heart disease: CNS stimulants increase catecholamine activity, leading to elevated heart rate, increased blood pressure, and heightened myocardial oxygen demand. In clients with symptomatic heart disease, this can precipitate angina, arrhythmias, myocardial infarction, or sudden cardiac death, making this the most critical finding before initiating therapy. C. Significant weight gain: CNS stimulants are more commonly associated with appetite suppression and weight loss rather than weight gain. While significant weight changes should be noted, they are not immediately dangerous and do not pose the same acute cardiovascular risk as underlying heart disease. D. Extreme fatigue: Fatigue may be an indication for stimulant therapy or an underlying condition requiring assessment. It is important to consider the cause, but fatigue alone does not pose an acute risk for adverse reactions from CNS stimulants and is less immediately concerning than symptomatic heart disease.